Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Between Oct 12 and Oct 20, 2026, enterprise software and infrastructure vendors moved together to operationalize agentic AI. Salesforce agreed to buy Braze to add real-time customer-engagement data. ServiceNow launched AI Passport and expanded its agent-governance control tower. Intuit pushed AI into accounting and into international markets. Cisco, NVIDIA, Marvell and Hesai build out the networking, silicon, local-compute and physical-AI data layers beneath them. A counter-current of AI-safety concern, shown by OpenAI's safety-transparency lead quitting and OpenAI's response of adding monitors to training runs, shows trust and governance becoming a gating factor.
Across mid- and small-cap issuers, October 2026 brought a cluster of governance events: interim CEO handoffs (Fox Factory, Keyser's move to advisor), board refreshes, shareholder-vote-driven restructurings (Odyssey's merger vote and 1-for-25 reverse split, the NGEx spin-out) and a contested situation at Boardwalktech, where ZenaTech asked regulators to intervene. Several of these are tied to weak results or reduced guidance (Fox Factory's Q3 miss and Marucci divestiture), and boards are leaning on unanimous-recommendation and 'accomplished executive' messaging to project stability. Steadier names such as Vivendi (lower net debt, Gameloft-led revenue growth) and Value Line (regular $0.35 dividend) are a contrast, so overall sentiment is mixed.
In the second week of October 2026, Palantir announced a cluster of AI partnerships with Customers Bank, Ondas (Regna AI), Armada and Surf Air Mobility (OperatorOS). Four Seeking Alpha analysts turned or stayed bullish, citing customer expansion, net dollar retention and a Goldman Sachs upgrade. In contrast, J.P. Morgan's Seth Seifman describes weak, sour sentiment in aerospace and defense (a Leidos downgrade, Boeing cash-flow doubts) even with the broader market near highs. Fiscal 2027 budget uncertainty after the Nov. 3 midterms hangs over that group, while quantum names such as D-Wave look stretched on valuation.
October 2026 brings a cluster of oncology catalysts. Positive CHMP opinions (RASONQUE in pancreatic cancer, an updated Libtayo regimen), an FDA approval (Tecentriq in adjuvant dMMR colon cancer) and heavy ESMO data from AbbVie, intismeran and others support a constructive sector tone. Meanwhile AstraZeneca's AI-enabled 'lab of the future' and agentic biologics design, plus ADC-focused small caps like Akari and consolidation such as McKesson/CD&R's Option Care Health deal, point to capital and talent moving toward AI-accelerated, ADC-centred oncology pipelines.
Small and mid-cap biotechs (MindWalk, Everest, Idorsia, Akari, Ernexa, Prelude, MapLight) are hiring translational, discovery and business-development leaders ahead of IND filings and Phase 1/2 readouts. Royalty and milestone income (BioArctic's Leqembi royalties, VivoSim's Eli Lilly milestones, Lilly's obesity and diabetes demand) is funding them. Idorsia's CEO handover and Kimi models being jailbroken to give bioweapon instructions show governance and AI-biosecurity risk building alongside the growth. The AI-finance link is thin: the facts contain no direct fintech or trading content, so the AI angle is mostly biosecurity and the finance angle is royalty and milestone revenue.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedSupermicro Announces Intelligent In-Store Retail Solutions in Collaboration with a Broad Range of Industry Partners
“Supermicro Announces Intelligent In-Store Retail Solutions in Collaboration with a Broad Range of Industry Partners Innovative technologies enable retailers to implement intelligent stores at scale to deliver smarter, more responsive shopping experiences Industry partners to display production-ready AI solutions for lo…”
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
“GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif…”
Aehr Test (AEHR) Q2 2026 Earnings Call Transcript
“Aehr Test (AEHR) Q2 2026 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, January 8, 2026 at 5:00 p.m…”
Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
“Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 Arteris, Inc. Arteris joins the ranks of Google, Nvidia, Adidas, Walmart, and more in Fast Company’s annual World’s Most Innovative Companies of 2026 list…”
The Agentic Era Redefines Customer Intimacy as AI is Set to Become the Primary Brand Interface
“The Agentic Era Redefines Customer Intimacy as AI is Set to Become the Primary Brand Interface With AI agents leading customer interactions, new Amdocs global research shows CSPs must embed trust, transparency, and distinct personalities into every AI-led experience to drive the next generation of personalization JERSE…”
Stocks Rally on a Push for Diplomacy to End US-Iran War
“Stocks Rally on a Push for Diplomacy to End US-Iran War The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.66%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.81%…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Verified SEC figures show Nvidia's cost of revenue rose about 3.8 times in two fiscal years. A survey says every respondent plans to use AI agents, but company data and trust lag. That survey's source failed our check on all 11 claims we tested, so we flag it and lean on the data that held.
SEC-filed figures show Micron nearly doubled its capital spending in fiscal 2025 and now holds about 2.5 times the cash it had a year earlier. Analyst enthusiasm for power, data-center and quantum stocks rests on sources that held up only about half the time in our checks.
Companies from Manulife to Box customers are rolling out AI agents, and funding is flowing. But a trade-press study reports that in 'data laggard' firms, AI can reach 30% or less of company data. That source has a poor measured record, so we flag it as a claim, not a fact.
Every company surveyed by MIT Technology Review plans to use AI agents within two years, yet firms with weak data give those agents access to 30% or less of it. Only some of this is firmly established: that survey's source scores 0% on our reliability check, and the Nvidia figures are SEC-verified.
Adobe's weak guidance, Alphabet's negative free cash flow, and a wave of safety-driven departures from Anthropic, Google and OpenAI show investors and insiders both demanding proof, not promises — even as California moves first to regulate AI's reach into children's lives.
A single summit produced roughly $950 billion in AI infrastructure deals and locked Nvidia into South Korea's memory supply chain, while one research firm says Wall Street is still underpricing the memory chip boom behind it. Here's what's verified, what's just one analyst's call, and what's still speculative.
C3.ai's CEO sold $4.8 million in stock the same week the industry's biggest AI-agent-trust survey turned out unreliable on 11 checked claims, even as Manulife, Box and a wave of banking and healthcare startups commit real budgets. Via News separates the verified from the unverified.
Google now lets users strip visible watermarks from Gemini-made images, video and music — a move that cuts against the story of an industry rushing toward stronger AI-content labeling, and lands the same week OpenAI lost another senior executive.
Nvidia and South Korea's chipmakers signed roughly $950 billion in new AI agreements in July, including a deal to help secure Nvidia's HBM memory supply from SK Hynix, even as chip stocks logged a sharp correction and the Nasdaq 100 hit a 2.75-month low. Via News traces the deals, earnings and balance-sheet data behind the divergence.
A late-July selloff cut deep into AI-chip stocks — Micron fell nearly 40% from its peak — even as Nvidia expanded its SK hynix memory deal, GlobalFoundries signed a $300M federal photonics award, and Skyworks-Qorvo named a combined leadership team. The data show a maturing boom repricing risk, not a broken one.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.